Richard R. Kew
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Richard R. Kew has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Glenda Trujillo
Department of Pathology, Stony Brook University School of Medicine, Stony Brook, NY 11794-8691, USA
4 shared publicationsJianhua Zhang
Department of Pathology, Stony Brook University School of Medicine, Stony Brook, NY 11794-8691
3 shared publicationsStephen J. DiMartino
Department of Pathology, Stony Brook University School of Medicine, Stony Brook, NY 11794-8691, USA
3 shared publicationsAnisha B. Shah
Department of Pathology, Health Sciences Center, Stony Brook University School of Medicine, Stony Brook, NY 11794-8691, USA
2 shared publicationsDavid M. Habiel
Department of Pathology, Stony Brook University School of Medicine, Stony Brook, NY 11794-8691
2 shared publicationsMahalakshmi Ramadass
Department of Pathology, Stony Brook University School of Medicine, Stony Brook, NY 11794-8691
2 shared publications
Latest Publications
- 1 December 2011
- Published by Elsevier in Molecular Immunology
- Vol. 49 (3) , 495-503
Cofactor regulation of C5a chemotactic activity in physiological fluids. Requirement for the vitamin D binding protein, thrombospondin-1 and its receptors
- 1 December 2011
- Published by Elsevier in Molecular Immunology
- Vol. 49 (3) , 495-503
Cofactor regulation of C5a chemotactic activity in physiological fluids. Requirement for the vitamin D binding protein, thrombospondin-1 and its receptors
- 1 May 2010
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
- Vol. 1803 (5) , 623-629
Identification of two distinct cell binding sequences in the vitamin D binding protein
- 1 May 2010
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
- Vol. 1803 (5) , 623-629
Identification of two distinct cell binding sequences in the vitamin D binding protein
- 1 March 2007
- Published by Elsevier in Molecular Immunology
- Vol. 44 (9) , 2370-2377
Upregulation of Vitamin D binding protein (Gc-globulin) binding sites during neutrophil activation from a latent reservoir in azurophil granules
- 1 March 2007
- Published by Elsevier in Molecular Immunology
- Vol. 44 (9) , 2370-2377
Upregulation of Vitamin D binding protein (Gc-globulin) binding sites during neutrophil activation from a latent reservoir in azurophil granules
- 1 March 2006
- Published by Elsevier in Molecular Immunology
- Vol. 43 (8) , 1109-1115
Selective inhibition of the C5a chemotactic cofactor function of the Vitamin D binding protein by 1,25(OH)2 Vitamin D3
- 1 March 2006
- Published by Elsevier in Molecular Immunology
- Vol. 43 (8) , 1109-1115
Selective inhibition of the C5a chemotactic cofactor function of the Vitamin D binding protein by 1,25(OH)2 Vitamin D3
- Open Access
- 15 February 2001
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 166 (4) , 2688-2694
Elastase Controls the Binding of the Vitamin D-Binding Protein (Gc-Globulin) to Neutrophils: A Potential Role in the Regulation of C5a Co-Chemotactic Activity
The vitamin D-binding protein (DBP) binds to the plasma membranes of numerous cell types and mediates a diverse array of cellular functions. DBP bound to the surface of leukocytes serves as a co-chemotactic factor for C5a, significantly enhancing the chemotactic activity of pM concentrations of C5a. This study investigated the regulation of DBP binding to neutrophils as a possible key step in the process of chemotaxis enhancement to C5a. Using radioiodinated DBP as a probe, neutrophils released 70% of previously bound DBP into the extracellular media during a 60-min incubation at 37°C. This was suppressed by serine protease inhibitors (PMSF, Pefabloc SC), but not by metallo- or thiol-protease inhibitors. DBP shed from neutrophils had no detectable alteration in its m.w., suggesting that a serine protease probably cleaves the DBP binding site, releasing DBP in an unaltered form. Cells treated with PMSF accumulate DBP vs time with over 90% of the protein localized to the plasma membrane. Purified neutrophil plasma membranes were used to screen a panel of protease inhibitors for their ability to suppress shedding of the DBP binding site. Only inhibitors to neutrophil elastase prevented the loss of membrane DBP-binding capacity. Moreover, treatment of intact neutrophils with elastase inhibitors prevented the generation of C5a co-chemotactic activity from DBP. These results indicate that steady state binding of DBP is essential for co-chemotactic activity, and further suggest that neutrophil elastase may play a critical role in the C5a co-chemotactic mechanism.
- 15 February 2001
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 166 (4) , 2688-2694
Open AccessElastase Controls the Binding of the Vitamin D-Binding Protein (Gc-Globulin) to Neutrophils: A Potential Role in the Regulation of C5a Co-Chemotactic Activity
The vitamin D-binding protein (DBP) binds to the plasma membranes of numerous cell types and mediates a diverse array of cellular functions. DBP bound to the surface of leukocytes serves as a co-chemotactic factor for C5a, significantly enhancing the chemotactic activity of pM concentrations of C5a. This study investigated the regulation of DBP binding to neutrophils as a possible key step in the process of chemotaxis enhancement to C5a. Using radioiodinated DBP as a probe, neutrophils released 70% of previously bound DBP into the extracellular media during a 60-min incubation at 37°C. This was suppressed by serine protease inhibitors (PMSF, Pefabloc SC), but not by metallo- or thiol-protease inhibitors. DBP shed from neutrophils had no detectable alteration in its m.w., suggesting that a serine protease probably cleaves the DBP binding site, releasing DBP in an unaltered form. Cells treated with PMSF accumulate DBP vs time with over 90% of the protein localized to the plasma membrane. Purified neutrophil plasma membranes were used to screen a panel of protease inhibitors for their ability to suppress shedding of the DBP binding site. Only inhibitors to neutrophil elastase prevented the loss of membrane DBP-binding capacity. Moreover, treatment of intact neutrophils with elastase inhibitors prevented the generation of C5a co-chemotactic activity from DBP. These results indicate that steady state binding of DBP is essential for co-chemotactic activity, and further suggest that neutrophil elastase may play a critical role in the C5a co-chemotactic mechanism.